Driehaus Capital Management’s Twist Bioscience TWST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$105M Buy
1,022,526
+437,830
+75% +$28.5M 0.61% 46
2026
Q1
$27.8M Buy
+584,696
New +$26.2M 0.2% 158
2024
Q3
Sell
-388,643
Closed -$19.2M 454
2024
Q2
$19.2M Buy
388,643
+150,260
+63% +$6.13M 0.19% 153
2024
Q1
$8.18M Buy
+238,383
New +$8.6M 0.08% 252
2021
Q2
Sell
-119,082
Closed -$14.7M 520
2021
Q1
$14.7M Sell
119,082
-193,506
-62% -$29.4M 0.22% 145
2020
Q4
$44.2M Sell
312,588
-138,548
-31% -$15.4M 0.71% 33
2020
Q3
$34.3M Sell
451,136
-93,643
-17% -$5.83M 0.7% 30
2020
Q2
$24.7M Buy
544,779
+96,683
+22% +$3.47M 0.6% 44
2020
Q1
$13.7M Buy
448,096
+84,531
+23% +$2.27M 0.46% 63
2019
Q4
$7.63M Buy
363,565
+5,564
+2% +$130K 0.2% 131
2019
Q3
$8.55M Buy
358,001
+47,312
+15% +$1.38M 0.28% 98
2019
Q2
$9.01M Buy
310,689
+247,615
+393% +$6.55M 0.28% 96
2019
Q1
$1.46M Sell
63,074
-16,406
-21% -$371K 0.05% 255
2018
Q4
$1.83M Buy
+79,480
New +$1.76M 0.08% 233

Other funds holding TWST

Driehaus Capital Management's TWST Position: Q2 2026 in Review

Driehaus Capital Management increased its Twist Bioscience (TWST) stake by 75% in Q2 2026, buying an estimated $28.5M and bringing the position to 1,022,526 shares worth $105M. The position accounts for 0.61% of the portfolio, ranked #46.

Driehaus Capital Management first reported a position in TWST in Q4 2018 and has held it in 14 quarters since. 337 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

  • Driehaus Capital Management held 1,022,526 shares of Twist Bioscience worth $105M as of Q2 2026.
  • Driehaus Capital Management bought 437,830 Twist Bioscience shares in Q2 2026, an estimated $28.5M.
  • Twist Bioscience made up 0.61% of Driehaus Capital Management's portfolio in Q2 2026, its #46 holding.
  • Driehaus Capital Management first reported a position in Twist Bioscience in Q4 2018 and has held it in 14 quarters since.
  • 337 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.